<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v= 2。 17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20231025203621&amp;utm_campaign=pubmed-2&amp;utm_medium =rss<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20231025203621&amp;utm_campaign=pubmed-2&amp;utm_medium=rss" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 26 日星期四 00:36:22 +0000</lastbuilddate><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>部分口服治疗感染性心内膜炎的临床实施：丹麦 POETry 研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37879115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>结论：临床实施 POET 方案后，几乎一半可能患有 IE 的患者接受了口服降压抗生素治疗。IV 组患者有更严重的不良结果危险因素。在 6 个月的随访中，有PO 组的主要结局发生率较低、全因死亡率发生率较低以及住院时间较短，但在数字上存在显着差异，但在统计学上没有显着差异。由于该研究的观察性设计... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 25 日：ehad715。doi：10.1093/eurheartj/ehad715。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在心内膜炎部分口服治疗 (POET) 试验中，病情稳定的左侧感染性心内膜炎 (IE) 患者被随机分配接受口服降压抗生素治疗 (PO) 或传统的持续静脉抗生素治疗 (IV)，结果显示6 个月后非劣效性。在这项研究中，检验了口服降压 POET 方案的第一个指南驱动的实施临床。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：2019 年 5 月至 2020 年 12 月期间诊断出的由金黄色葡萄球菌、粪肠球菌、链球菌属或凝固酶阴性葡萄球菌引起的 IE 患者可能适合开始口服降压抗生素治疗，具体由治疗医生酌情决定。最终完成抗生素治疗的患者的复合主要结局包括栓塞事件、计划外心脏手术、菌血症复发和 6 个月内全因死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共 562 名 IE 患者[中位年龄 74 岁（IQR，四分位数范围，65-80），70% 男性]可能是 IE 的候选者；240 名患者（43%）接受 PO 治疗，322 名患者（57%）接受 IV 治疗。 IV 组中有更多患者患有金黄色葡萄球菌引起的 IE，或患有心内脓肿，或安装起搏器，并且更多患者接受了手术治疗。PO 组中有 30 名 (13%) 患者发生了主要结局， IV 组有 59 名 (18%) 患者死亡 (P = .051)；PO 组有 20 名 (8%) 患者死亡，而 IV 组有 46 名 (14%) 患者死亡 (P = .024)。接受治疗的患者的中位住院时间较短[PO 24 天 (IQR 17-36) 与 IV 43 天 (IQR 32-51)，P &lt; .001]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：临床实施 POET 方案后，几乎一半可能患有 IE 的患者接受了口服降压抗生素治疗。IV 组患者有更严重的不良结果危险因素。在 6 个月的随访中，有PO 组的主要结局发生率较低、全因死亡率发生率较低以及住院时间较短，但在数字上存在显着差异，但无统计学意义。由于研究的观察性设计，较低的死亡率可能在一定程度上反映了选择偏倚和未测量的混杂因素。PO 方案的临床实施似乎可行且安全。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37879115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37879115</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad715>10.1093/eurheartj/ehad715</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37879115</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>米娅·玛丽·普里斯-海杰</dc:creator><dc:creator>朱莉·格鲁德·胡曼德</dc:creator><dc:creator>英格丽德·特里·伦茨</dc:creator><dc:creator>拉斯穆斯·博·哈塞尔巴赫</dc:creator><dc:creator>乔纳斯·艾格伦德·波尔森</dc:creator><dc:creator>尼古拉伊勒曼</dc:creator><dc:creator>娜娜·科伯</dc:creator><dc:creator>玛琳·林伯格·托夫特鲁普</dc:creator><dc:creator>劳格·奥斯特加德</dc:creator><dc:creator>莫滕·达尔斯加德</dc:creator><dc:creator>丹尼尔·法尔霍特-杰普森</dc:creator><dc:creator>马琳·温伯格</dc:creator><dc:creator>乌尔里克·克里斯蒂安森</dc:creator><dc:creator>尼尔斯·艾斯克·布鲁恩</dc:creator><dc:creator>埃米尔·福斯伯尔</dc:creator><dc:creator>克劳斯·莫泽</dc:creator><dc:creator>卡斯帕·卡马克·艾弗森</dc:creator><dc:creator>亨宁·邦德加德</dc:creator><dc:date>2023-10-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>部分口服治疗感染性心内膜炎的临床实施：丹麦 POETry 研究</dc:title><dc:identifier>下午：37879115</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad715</dc:identifier></item><item><title>怀孕期间解剖的开放导管之一</title><link/>https://pubmed.ncbi.nlm.nih.gov/37879111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 25 日：ehad687。doi：10.1093/eurheartj/ehad687。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37879111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37879111</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad687>10.1093/eurheartj/ehad687</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37879111</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>安妮·J·科佩拉尔</dc:creator><dc:creator>亚历克斯·J·埃金克</dc:creator><dc:creator>约翰内斯·米赫·戈</dc:creator><dc:date>2023-10-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>怀孕期间解剖的开放导管之一</dc:title><dc:identifier>下午:37879111</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad687</dc:identifier></item><item><title>射血分数保留的肥胖和心力衰竭患者的治疗向前迈进了一步</title><link/>https://pubmed.ncbi.nlm.nih.gov/37879100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 25 日：ehad674。doi：10.1093/eurheartj/ehad674。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37879100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37879100</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad674>10.1093/eurheartj/ehad674</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37879100</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>乔凡娜·柳佐</dc:creator><dc:creator>卡罗·帕特罗诺</dc:creator><dc:date>2023-10-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>射血分数保留的肥胖和心力衰竭患者的治疗向前迈进了一步</dc:title><dc:identifier>下午：37879100</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad674</dc:identifier></item><item><title>急性冠脉综合征支架植入替格瑞洛单药治疗后 1 个月内停用阿司匹林：T-PASS 随机非劣效性试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>背景：替格瑞洛单药治疗植入药物洗脱支架 (DES) 后 1 个月内停用阿司匹林尚未专门针对急性冠脉综合征 (ACS) 患者进行评估。本研究的目的是探讨在&lt;1对于 ACS 患者的不良心血管和出血事件，一个月的双重抗血小板治疗 (DAPT) 不劣于 12 个月的基于替格瑞洛的 DAPT。方法：在这项随机、开放标签的研究中，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 25 日。doi：10.1161/CIRCULATIONAHA.123.066943。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>替格瑞洛单药治疗植入药物洗脱支架 (DES) 后 1 个月内停用阿司匹林尚未专门针对急性冠脉综合征 (ACS) 患者进行评估。本研究的目的是探讨在&lt;1一个月的双联抗血小板治疗 (DAPT) 对于 ACS 患者的不良心血管和出血事件不劣于基于替格瑞洛的 DAPT 12 个月。<b>方法：</b>在这项随机、开放标签、非劣效性试验中，2850 名 ACS 患者接受了韩国 24 个中心的 DES 植入被随机分配 (1:1)，接受 DAPT 1 个月以内的替格瑞洛单药治疗（90 毫克，每天两次）（n=1426）或基于替格瑞洛的 DAPT 12 个月（n=1424） ）于2019年4月24日至2022年5月31日之间。主要终点是指数后1年的净临床获益，包括全因死亡、心肌梗死、明确或可能的支架血栓形成、中风和大出血<b>结果：</b>在 2850 名随机分组的患者中（平均年龄 61 岁；40% ST 段抬高型心肌梗死），2823 名患者（99.0% ) 完成了试验。在 DAPT 1 个月内接受替格瑞洛单药治疗的组中，阿司匹林在中位 16 天（四分位距，12 至 25 天）时停用。主要终点发生在该组中 40 名患者 (2.8%) 中在 &lt;1 个月 DAPT 后接受替格瑞洛单药治疗，以及基于替格瑞洛的 12 个月 DAPT 组中的 73 名患者 (5.2%)（风险比 [HR]，0.54 [95% CI，0.37-0.80]； <i>P</i> &lt;0.001）非劣效性； <i>P</i> = 0.002 为优效性）。这一发现在符合方案人群的敏感性分析中是一致的。与 12 个月 DAPT 组相比，&lt;1 个月 DAPT 组后替格瑞洛单药治疗组的大出血发生率显着降低组（1.2% vs 3.4%；HR，0.35 [95% CI，0.20-0.61]； <i>P</i> &lt;0.001）。<b>结论：</b>本研究提供的证据表明，替格瑞洛单药治疗 1 个月内停用阿司匹林不仅不劣于，而且优于 12 个月DAPT 涉及接受 DES 植入的 ACS 患者的 1 年综合结局，包括死亡、心肌梗塞、支架内血栓形成、中风和大出血，主要是由于大出血显着减少。在解释试验时应考虑非高危患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878786</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066943>10.1161 / CIRCULATIONAHA.123.066943</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878786</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>洪成镇</dc:creator><dc:creator>李承俊</dc:creator><dc:creator>徐永成</dc:creator><dc:creator>尹庆浩</dc:creator><dc:creator>姜泰秀</dc:creator><dc:creator>申尚勋</dc:creator><dc:creator>权成佑</dc:creator><dc:creator>李俊元</dc:creator><dc:creator>赵德奎</dc:creator><dc:creator>朴钟宽</dc:creator><dc:creator>裴张焕</dc:creator><dc:creator>黄哲康</dc:creator><dc:creator>金承焕</dc:creator><dc:creator>李勇俊</dc:creator><dc:creator>安哲民</dc:creator><dc:creator>金正善</dc:creator><dc:creator>金秉国</dc:creator><dc:creator>高英国</dc:creator><dc:creator>崔东勋</dc:creator><dc:creator>张良洙</dc:creator><dc:creator>洪明基</dc:creator><dc:creator>T-PASS 调查员</dc:creator><dc:date>2023-10-25</dc:date><dc:source>循环</dc:source><dc:title>急性冠脉综合征支架植入替格瑞洛单药治疗后 1 个月内停用阿司匹林：T-PASS 随机非劣效性试验</dc:title><dc:identifier>下午:37878786</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066943</dc:identifier></item><item><title>心血管器械的监管——我们为何关心</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878318/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3903。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878318/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878318</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3903>10.1001/jamacardio.2023.3903</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878318</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>克莱德·W·扬西</dc:creator><dc:creator>帕特里克·T·奥加拉</dc:creator><dc:creator>罗伯特·奥博诺</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>心血管器械的监管——我们为何关心</dc:title><dc:identifier>下午:37878318</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3903</dc:identifier></item><item><title>通过突破性设备计划调整美国机构对心血管设备的政策</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878306/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>结论和相关性：尽管证据不代表 CMS 受益人且利益和风险持续存在不确定性，但 BDP 可能会为新的、昂贵的设备提供更高的自动医疗保险报销资格。为了确保生成最佳证据来指导临床护理，FDA 可以应用更多对 BDP 资格的选择性，在适当时指定撤销突破性指定的客观标准，并确保及时生成上市后证据，而 CMS 可以... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3819。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：美国食品和药物管理局 (FDA) 和医疗保险和医疗补助服务中心 (CMS) 具有不同的法定权限；FDA 评估医疗器械市场授权的安全性和有效性，而 CMS 则确定其承保范围是否“合理且必要”。 CMS 最近颁布了政策，自动为 FDA 突破性设备计划 (BDP) 指定后授权的新的昂贵设备提供补充报销，并于 2023 年 6 月发布了新的新兴技术过渡覆盖途径通知，加速了突破性设备的覆盖。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">观察：为了激励创新，FDA 在设备开发早期授予突破性称号，以加快市场授权，并可以接受收益和风险方面更大的不确定性，具体取决于上市后证据的生成。自 2020 年以来，突破性称号实际上自动使设备有资格获得补充医疗保险报销在 CMS 放弃了一项长期要求，即设备必须为受益人展示“实质性临床改善”后。使用公开信息，心血管设备的 3 个示例表明，BDP 可能允许 FDA 基于不太严格的证据（例如单臂试验）进行授权重点关注具有短期随访的替代终点，其参与者通常不代表 Medicare 受益人。在 1 个案例中，突破性指定使用于支持批准的试验的注册人数减少了 30%。某些设备的初步积极结果仍然未经验证，在一种情况下，甚至部分无效，通过上市后研究。制造商还使用突破性称号来设定设备的价格，以促进额外的转嫁支付，导致 CMS 和健康的短期和长期成本更高护理系统。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：尽管证据不代表 CMS 受益人且利益和风险持续存在不确定性，但 BDP 可能会为新的、昂贵的设备提供更高的自动医疗保险报销资格。为了确保生成最佳证据来指导临床护理，FDA 可以应用更多选择性地选择 BDP 资格，在适当时指定撤销突破性指定的客观标准，并确保及时生成上市后证据，而 CMS 可以独立审查临床证据，就覆盖审查标准向制造商提供建议，并根据情况进行补充付款和长期设备报销临床结果获益和上市后证据生成。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878306/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878306</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3819>10.1001/jamacardio.2023.3819</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878306</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>奥斯曼·莫内尔</dc:creator><dc:creator>维奈·K·拉蒂</dc:creator><dc:creator>詹姆斯·约翰斯顿</dc:creator><dc:creator>约瑟夫·罗斯</dc:creator><dc:creator>桑克特·杜鲁瓦</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>通过突破性设备计划调整美国机构对心血管设备的政策</dc:title><dc:identifier>下午:37878306</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3819</dc:identifier></item><item><title>缺血性心室功能障碍的血运重建或药物治疗的可行性和结果：REVIVED-BCIS2 试验的预先指定二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>结论和相关性：本研究发现，活力测试并不能识别缺血性心肌病患者是否可以从 PCI 中获益。非存活心肌的范围（而非存活心肌的范围）与无事件生存率和左心室改善的可能性相关。功能。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3803。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在缺血性心室功能障碍血运重建 (REVIVED-BCIS2) 试验中，经皮冠状动脉介入治疗 (PCI) 并未改善缺血性左心室功能障碍患者的预后。 PCI 的获益仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：确定存活和失活心肌的范围对 PCI 有效性、预后和左心室功能改善的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：2013年8月28日至2020年3月19日期间招募的前瞻性开放标签随机临床试验，中位随访时间为3.4年（IQR，2.3-5.0年）。共有40名二级受试者在 700 名随机分配的患者中，有 610 名患者左心室射血分数小于或等于 35%，患有广泛的冠状动脉疾病，并且至少有 4 个心肌节段存在活力，但这些心肌节段在包括休息和接受盲法核心实验室活力表征的人。数据分析于2022年3月31日至2023年5月1日进行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：除了最佳药物治疗外，还需进行经皮冠状动脉介入治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：对心脏磁共振成像扫描和多巴酚丁胺负荷超声心动图进行盲法核心实验室分析，以量化存活和非存活心肌的范围，以左心室质量的绝对百分比表示。该亚组分析的主要结果是次要结局是全因死亡、心血管死亡、心力衰竭住院以及 6 个月时左心室功能改善。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：参与者的平均 (SD) 年龄为 69.3 (9.0) 岁。在 PCI 组中，258 名 (87%) 为男性，在最佳药物治疗组中，277 名 (88%) 为男性。分配到 PCI 的 295 名参与者中的 107 名和分配到单独最佳药物治疗的 315 名参与者中的 114 名发生了这种情况。存活或非存活心肌的范围与 PCI 对主要或任何次要结果的影响之间没有相互作用。在整个研究人群中，存活心肌的程度与主要结局（每增加 10% 的风险比，0.98；95% CI，0.93-1.04）或任何次要结局无关。，1.07；95% CI，1.00-1.15），全部-导致死亡、心血管死亡和左心室功能改善。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：本研究发现，活力测试并不能识别缺血性心肌病患者是否可以从 PCI 中获益。非存活心肌的范围（而非存活心肌的范围）与无事件生存率和左心室改善的可能性相关。功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT01920048。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878295</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3803>10.1001/jamacardio.2023.3803</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878295</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>迪瓦卡·佩雷拉</dc:creator><dc:creator>马修·瑞安</dc:creator><dc:creator>霍莉·P·摩根</dc:creator><dc:creator>约翰·P·格林伍德</dc:creator><dc:creator>马克·皮特里</dc:creator><dc:creator>马修·多德</dc:creator><dc:creator>罗珊·韦拉科迪</dc:creator><dc:creator>彼得·D·奥凯恩</dc:creator><dc:creator>皮尔·乔治·马西</dc:creator><dc:creator>穆罕默德·索海布·纳齐尔</dc:creator><dc:creator>亚历山德罗斯·帕帕克里斯提迪斯</dc:creator><dc:creator>纳夫泰吉·查哈尔</dc:creator><dc:creator>拉杰迪普·哈塔尔</dc:creator><dc:creator>萨阿德·M·埃扎德</dc:creator><dc:creator>斯塔姆·卡佩塔纳基斯</dc:creator><dc:creator>拉娜·迪克森</dc:creator><dc:creator>卡尔帕·德席尔瓦</dc:creator><dc:creator>亚当·K·麦克迪阿米德</dc:creator><dc:creator>迈克尔·S·马伯</dc:creator><dc:creator>特里萨·麦克唐纳</dc:creator><dc:creator>格里·P·麦肯</dc:creator><dc:creator>蒂姆·C·克莱顿</dc:creator><dc:creator>罗克西高级</dc:creator><dc:creator>阿梅代奥·奇里比里</dc:creator><dc:creator>REVIVED-BCIS2 研究人员</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>缺血性心室功能障碍的血运重建或药物治疗的可行性和结果：REVIVED-BCIS2 试验的预先指定二次分析</dc:title><dc:identifier>下午:37878295</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3803</dc:identifier></item><item><title>缺血性心肌病的心肌活力评估——被数据伤痕累累但仍然存活</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3846。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878293</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3846>10.1001/jamacardio.2023.3846</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878293</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>胡里奥·潘萨</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>缺血性心肌病的心肌活力评估——被数据伤痕累累但仍然存活</dc:title><dc:identifier>下午:37878293</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3846</dc:identifier></item><item><title>确定因射血分数降低的心力衰竭住院患者开始钠-葡萄糖协同转运蛋白 2 抑制剂治疗的障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3781。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878289</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3781>10.1001/jamacardio.2023.3781</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878289</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>凯瑟琳·阿奈斯·萨达尼安茨</dc:creator><dc:creator>杰弗里·施</dc:creator><dc:creator>拉拉·C·科维尔</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>确定因射血分数降低的心力衰竭住院患者开始钠-葡萄糖协同转运蛋白 2 抑制剂治疗的障碍</dc:title><dc:identifier>下午:37878289</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3781</dc:identifier></item><item><title>重新调整心力衰竭患者评估和管理的优先顺序</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3900。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878287</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3900>10.1001/jamacardio.2023.3900</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878287</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>詹姆斯·E·乌德尔森</dc:creator><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>罗伯特·奥博诺</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>重新调整心力衰竭患者评估和管理的优先顺序</dc:title><dc:identifier>下午:37878287</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3900</dc:identifier></item><item><title>推动医疗创新 - 注重为患者提供最佳护理的证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3823。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878282</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3823>10.1001/jamacardio.2023.3823</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878282</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>李·弗莱舍</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>推动医疗创新 - 注重为患者提供最佳护理的证据</dc:title><dc:identifier>下午:37878282</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3823</dc:identifier></item><item><title>确定射血分数降低的心力衰竭住院患者开始钠-葡萄糖协同转运蛋白 2 抑制剂治疗的障碍 - 回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37878275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 10 月 25 日。doi：10.1001/jamacardio.2023.3784。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37878275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37878275</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3784>10.1001/jamacardio.2023.3784</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37878275</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>雅各布·皮尔斯</dc:creator><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>斯蒂芬·J·格林</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>确定射血分数降低的心力衰竭住院患者开始钠-葡萄糖协同转运蛋白 2 抑制剂治疗的障碍 - 回复</dc:title><dc:identifier>下午:37878275</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3784</dc:identifier></item><item><title>未经治疗的主动脉瓣狭窄的死亡负担</title><link/>https://pubmed.ncbi.nlm.nih.gov/37877909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>结论：未经治疗的 AS 严重程度的所有级别的 AS 患者均具有较高的死亡风险。严重 AS 患者的主动脉瓣置换率仍然较低，这表明需要更多的研究来了解诊断障碍以及主动脉瓣置换的适当方法和时机。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 20 日：S0735-1097(23)07504-6。doi：10.1016/j.jacc.2023.09.796。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：美国心脏病学会/美国心脏协会指南建议根据超声心动图对主动脉瓣狭窄 (AS) 的严重程度进行评估和分级，分为轻度、中度或重度，并在 AS 严重时建议进行主动脉瓣置换术 (AVR)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：作者试图从当代大型真实世界数据库中描述未经治疗的 AS 的整个范围内的死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了来自 24 家美国医院（egnite 数据库，egnite）的去识别真实世界数据集，包括 1,669,536 份超声心动图报告（1,085,850 名患者）。年龄 >;18 岁的患者根据诊断的 AS 严重程度进行分类。检查了未经治疗的死亡率和治疗率使用 Kaplan-Meier (KM) 估计，并使用对数秩检验对结果进行比较。进行多变量风险分析以评估与全因死亡率的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 595,120 名进行了 AS 严重程度评估的患者中，KM 估计的 4 年未调整、未治疗、全因死亡率与 AS 诊断相关，包括无、轻度、轻度至中度、中度、中度至重度或严重率为 13.5% (95% CI: 13.3%-13.7%)、25.0% (95% CI: 23.8%-26.1%)、29.7% (95% CI: 26.8%-32.5%)、33.5% (95% CI)当根据治疗引起的信息审查进行调整时，结果相似 KM 估计的 4 年观察治疗率分别为 0.2%（95% CI：0.2%-0.2%）、1.0%（95% CI：0.7%-1.3%）、4.2 %（95% CI：2.0%-6.3 调整后，所有程度的 AS 严重程度均与死亡率增加相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：未经治疗的 AS 严重程度的所有级别的 AS 患者均具有较高的死亡风险。严重 AS 患者的主动脉瓣置换率仍然较低，这表明需要更多的研究来了解诊断障碍以及主动脉瓣置换的适当方法和时机。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37877909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877909</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.796>10.1016/j.jacc.2023.09.796</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37877909</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>菲利普·热内勒</dc:creator><dc:creator>拉胡尔·夏尔马</dc:creator><dc:creator>罗伯特·J·库贝杜</dc:creator><dc:creator>露西亚伦</dc:creator><dc:creator>奥马尔·阿卜杜勒法塔赫</dc:creator><dc:creator>康斯坦丁诺斯·P·库洛吉安尼斯</dc:creator><dc:creator>利奥·马尔科夫</dc:creator><dc:creator>穆斯塔法·纳吉布</dc:creator><dc:creator>萨米尔·R·卡帕迪亚</dc:creator><dc:creator>拉金德拉·R·马卡</dc:creator><dc:creator>维诺德·H·图拉尼</dc:creator><dc:creator>本杰明·范·博克斯特尔</dc:creator><dc:creator>大卫·J·科恩</dc:creator><dc:creator>迈克尔·多布尔斯</dc:creator><dc:creator>格伦·R·巴恩哈特</dc:creator><dc:creator>米歇尔·权</dc:creator><dc:creator>菲利普·皮巴罗</dc:creator><dc:creator>马丁·B·莱昂</dc:creator><dc:creator>琳达·D·吉拉姆</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>未经治疗的主动脉瓣狭窄的死亡负担</dc:title><dc:identifier>下午:37877909</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.796</dc:identifier></item><item><title>主动脉瓣狭窄：六年的历程</title><link/>https://pubmed.ncbi.nlm.nih.gov/37877908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 18 日：S0735-1097(23)07682-9。doi：10.1016/j.jacc.2023.10.001。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37877908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877908</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.10.001>10.1016/j.jacc.2023.10.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37877908</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>尤金·布劳瓦尔德</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>主动脉瓣狭窄：六年的历程</dc:title><dc:identifier>下午:37877908</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.10.001</dc:identifier></item><item><title> Evolut 低风险试验中主动脉瓣狭窄患者的 4 年结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37877907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 18 日：S0735-1097(23)07628-3。doi：10.1016/j.jacc.2023.09.813。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37877907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877907</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.813>10.1016/j.jacc.2023.09.813</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37877907</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>约翰·K·福雷斯特</dc:creator><dc:creator>G迈克尔·迪布</dc:creator><dc:creator>史蒂文·雅库波夫</dc:creator><dc:creator>赫马尔·加达</dc:creator><dc:creator>穆巴希尔·蒙塔兹</dc:creator><dc:creator>巴塞尔拉姆拉维</dc:creator><dc:creator>坦维尔·巴杰瓦</dc:creator><dc:creator>保罗·泰尔斯坦</dc:creator><dc:creator>迪迪埃·切切</dc:creator><dc:creator>黄健</dc:creator><dc:creator>迈克尔·J·里尔登</dc:creator><dc:creator>Evolut 低风险试验研究者</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Evolut 低风险试验中主动脉瓣狭窄患者的 4 年结果</dc:title><dc:identifier>下午:37877907</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.813</dc:identifier></item><item><title>法国年龄和性别与经导管主动脉瓣置换术的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37877906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>结论：在法国，年轻患者中 TAVR 的使用仍然不常见，主要限于高危患者。在患者人口统计、AVR 方式的选择和患者结果方面观察到重要的性别差异。还有其他研究评估了 TAVR 的长期影响需要在年轻患者中使用 TAVR，并需要评估 AVR 方式选择和结果中性别差异的前瞻性数据。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 11 日：S0735-1097(23)06649-4。doi：10.1016/j.jacc.2023.08.044。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：目前的指南建议根据年龄、合并症和手术风险选择手术主动脉瓣置换术（SAVR）或经导管主动脉瓣置换术（TAVR）。然而，来自美国的报告表明年轻患者中TAVR的应用正在迅速扩大。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：作者试图根据年龄和性别评估法国全国范围内 TAVR 的采用趋势。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：利用全国性的管理数据库，我们评估了 2015 年至 2020 年间 TAVR 使用情况、患者人口统计数据和院内结果的年龄和性别相关趋势。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有107,397例患者（44.0%女性）接受了孤立性主动脉瓣置换术（AVR）（59.1% TAVR，40.9% SAVR），在年龄&lt;65岁的患者中，TAVR比例增加了63.2%（P &lt;从 2015 年到 2020 年，这一比例为 0.001），但到 2020 年仍不常见，占所有 AVR 的 11.1%（女性 12.4%，男性 10.6%），而 TAVR 是 65 岁以上患者的主要治疗方式。在接受 TAVR 的患者中，Charlson 合并症年龄&lt;65岁的患者的死亡率指数（CCI）（趋势P = 0.119）和院内死亡率（趋势P = 0.740）保持不变，但无论性别，≥65岁的患者均有所下降（所有P &lt; 0.001）女性年龄较大（P &lt; 0.001），CCI 较低（P &lt; 0.001），更有可能接受 TAVR（P &lt; 0.001），并且院内死亡率较高（TAVR，P = 0.015；SAVR，P &lt; 0.001），尽管对年龄和 CCI 进行了调整，但该结果仍然存在。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在法国，年轻患者中 TAVR 的使用仍然不常见，主要限于高危患者。在患者人口统计、AVR 方式的选择和患者结果方面观察到重要的性别差异。还有其他研究评估了 TAVR 的长期影响需要在年轻患者中使用 TAVR，并需要评估 AVR 方式选择和结果中性别差异的前瞻性数据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37877906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877906</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.044>10.1016/j.jacc.2023.08.044</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37877906</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>格雷姆·普罗斯佩里-波塔</dc:creator><dc:creator>弗吉尼亚·阮</dc:creator><dc:creator>纳达夫·威尔纳</dc:creator><dc:creator>朱利安·德雷福斯</dc:creator><dc:creator>海伦·埃尔查尼诺夫</dc:creator><dc:creator>伊恩·G·伯沃什</dc:creator><dc:creator>摩根·米歇尔</dc:creator><dc:creator>埃里克·杜兰德</dc:creator><dc:creator>马丁·吉拉德</dc:creator><dc:creator>克里斯特尔·丁多夫</dc:creator><dc:creator>翁伯纳德</dc:creator><dc:creator>阿兰·克里比尔</dc:creator><dc:creator>亚历克·瓦哈尼安</dc:creator><dc:creator>卡琳·谢弗勒尔</dc:creator><dc:creator>大卫·梅西卡-泽图恩</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>法国年龄和性别与经导管主动脉瓣置换术的关系</dc:title><dc:identifier>下午:37877906</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.044</dc:identifier></item><item><title>欧洲与美国 TAVR 的采用情况：是似曾相识吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37877905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231025203621&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 11 日：S0735-1097(23)06650-0。doi：10.1016/j.jacc.2023.09.002。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37877905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877905</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.002>10.1016/j.jacc.2023.09.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37877905</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator>安东尼奥·科伦坡</dc:creator><dc:creator>皮尔·帕斯卡莱·莱昂内</dc:creator><dc:date>2023-10-25</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Adoption of TAVR in Europe vs the United States: Is it Deja-Vù?</dc:title><dc:identifier> pmid:37877905</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.002</dc:identifier></item><item><title> Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies</title><link/> https://pubmed.ncbi.nlm.nih.gov/37877288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025203621&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The PDS was associated with a lower risk of CVD, including CHD and stroke, and a more favorable blood lipid and inflammatory profile, in 3 large prospective cohorts. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 25. doi: 10.1161/CIRCULATIONAHA.123.065551. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The plant-based Portfolio dietary pattern includes recognized cholesterol-lowering foods (ie, plant protein, nuts, viscous fiber, phytosterols, and plant monounsaturated fats) shown to improve several cardiovascular disease (CVD) risk factors in randomized controlled trials. However, there is limited evidence on the role of long-term adherence to the diet and CVD risk. The primary objective was to examine the relationship between the Portfolio Diet Score (PDS) and the risk of total CVD, coronary heart disease (CHD), and stroke. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We prospectively followed 73924 women in the Nurses&#39; Health Study (1984-2016), 92346 women in the Nurses&#39; Health Study II (1991-2017), and 43970 men in the Health Professionals Follow-up Study (1986-2016) without CVD or cancer at baseline. Diet was assessed using validated food frequency questionnaires at baseline and every 4 years using a PDS that positively ranks plant protein (legumes), nuts and seeds, viscous fiber sources, phytosterols (mg/day), and plant monounsaturated fat sources, and negatively ranks foods high in saturated fat and cholesterol. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: During up to 30 years of follow-up, 16917 incident CVD cases, including 10666 CHD cases and 6473 strokes, were documented. After multivariable adjustment for lifestyle factors and a modified Alternate Healthy Eating Index (excluding overlapping components), comparing the highest with the lowest quintile, participants with a higher PDS had a lower risk of total CVD (pooled hazard ratio [HR], 0.86 [95% CI, 0.81-0.92]; <i>P</i> <sub>trend</sub> &lt;0.001), CHD (pooled HR, 0.86 [95% CI, 0.80-0.93]; <i>P</i> <sub>trend</sub> =0.0001), and stroke (pooled HR, 0.86 [95% CI, 0.78-0.95]; <i>P</i> <sub>trend</sub> =0.0003). In addition, a 25-percentile higher PDS was associated with a lower risk of total CVD (pooled HR, 0.92 [95% CI, 0.89-0.95]), CHD (pooled HR, 0.92 [95% CI, 0.88-0.95]), and stroke (pooled HR, 0.92 [95% CI, 0.87-0.96]). Results remained consistent across sensitivity and most subgroup analyses, and there was no evidence of departure from linearity for CVD, CHD, or stroke. In a subset of participants, a higher PDS was associated with a more favorable blood lipid and inflammatory profile. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The PDS was associated with a lower risk of CVD, including CHD and stroke, and a more favorable blood lipid and inflammatory profile, in 3 large prospective cohorts.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37877288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37877288</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065551>10.1161/CIRCULATIONAHA.123.065551</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37877288</guid><pubDate> Wed, 25 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Andrea J Glenn</dc:creator><dc:creator> Marta Guasch-Ferré</dc:creator><dc:creator> Vasanti S Malik</dc:creator><dc:creator> Cyril WC Kendall</dc:creator><dc:creator> JoAnn E Manson</dc:creator><dc:creator> Eric B Rimm</dc:creator><dc:creator> Walter C Willett</dc:creator><dc:creator> Qi Sun</dc:creator><dc:creator> David JA Jenkins</dc:creator><dc:creator> Frank B Hu</dc:creator><dc:creator> John L Sievenpiper</dc:creator><dc:date> 2023-10-25</dc:date><dc:source> Circulation</dc:source><dc:title> Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies</dc:title><dc:identifier> pmid:37877288</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065551</dc:identifier></item><item><title> Defining iron deficiency in patients with heart failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37875635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025203621&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Oct 24. doi: 10.1038/s41569-023-00951-6. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37875635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37875635</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00951-6>10.1038/s41569-023-00951-6</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37875635</guid><pubDate> Tue, 24 Oct 2023 06:00:00 -0400</pubDate><dc:creator> John GF Cleland</dc:creator><dc:date> 2023-10-24</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Defining iron deficiency in patients with heart failure</dc:title><dc:identifier> pmid:37875635</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00951-6</dc:identifier></item><item><title> Population immunity predicts evolutionary trajectories of SARS-CoV-2</title><link/> https://pubmed.ncbi.nlm.nih.gov/37875109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025203621&amp;v=2.17.9.post6+86293ac<description> The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, and antigenic changes that reduce cross-immunity induced by previous infections or vaccinations. How this functional variation shapes global evolution has remained unclear. Here, we establish a predictive fitness model for SARS-CoV-2 that integrates antigenic and intrinsic selection. The model is informed by tracking of... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Oct 11:S0092-8674(23)01076-0. doi: 10.1016/j.cell.2023.09.022. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, and antigenic changes that reduce cross-immunity induced by previous infections or vaccinations. How this functional variation shapes global evolution has remained unclear. Here, we establish a predictive fitness model for SARS-CoV-2 that integrates antigenic and intrinsic selection. The model is informed by tracking of time-resolved sequence data, epidemiological records, and cross-neutralization data of viral variants. Our inference shows that immune pressure, including contributions of vaccinations and previous infections, has become the dominant force driving the recent evolution of SARS-CoV-2. The fitness model can serve continued surveillance in two ways. First, it successfully predicts the short-term evolution of circulating strains and flags emerging variants likely to displace the previously predominant variant. Second, it predicts likely antigenic profiles of successful escape variants prior to their emergence.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37875109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37875109</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.09.022>10.1016/j.cell.2023.09.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37875109</guid><pubDate> Tue, 24 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Matthijs Meijers</dc:creator><dc:creator> Denis Ruchnewitz</dc:creator><dc:creator> Jan Eberhardt</dc:creator><dc:creator> Marta Łuksza</dc:creator><dc:creator> Michael Lässig</dc:creator><dc:date> 2023-10-24</dc:date><dc:source> Cell</dc:source><dc:title> Population immunity predicts evolutionary trajectories of SARS-CoV-2</dc:title><dc:identifier> pmid:37875109</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.022</dc:identifier></item><item><title> Human MCTS1-dependent translation of JAK2 is essential for IFN-γ immunity to mycobacteria</title><link/> https://pubmed.ncbi.nlm.nih.gov/37875108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025203621&amp;v=2.17.9.post6+86293ac<description> Human inherited disorders of interferon-gamma (IFN-γ) immunity underlie severe mycobacterial diseases. We report X-linked recessive MCTS1 deficiency in men with mycobacterial disease from kindreds of different ancestries (from China, Finland, Iran, and Saudi Arabia). Complete deficiency of this translation re-initiation factor impairs the translation of a subset of proteins, including the kinase JAK2 in all cell types tested, including T lymphocytes and phagocytes. JAK2 expression is... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Oct 18:S0092-8674(23)01078-4. doi: 10.1016/j.cell.2023.09.024. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Human inherited disorders of interferon-gamma (IFN-γ) immunity underlie severe mycobacterial diseases. We report X-linked recessive MCTS1 deficiency in men with mycobacterial disease from kindreds of different ancestries (from China, Finland, Iran, and Saudi Arabia). Complete deficiency of this translation re-initiation factor impairs the translation of a subset of proteins, including the kinase JAK2 in all cell types tested, including T lymphocytes and phagocytes. JAK2 expression is sufficiently low to impair cellular responses to interleukin-23 (IL-23) and partially IL-12, but not other JAK2-dependent cytokines. Defective responses to IL-23 preferentially impair the production of IFN-γ by innate-like adaptive mucosal-associated invariant T cells (MAIT) and γδ T lymphocytes upon mycobacterial challenge. Surprisingly, the lack of MCTS1-dependent translation re-initiation and ribosome recycling seems to be otherwise physiologically redundant in these patients. These findings suggest that X-linked recessive human MCTS1 deficiency underlies isolated mycobacterial disease by impairing JAK2 translation in innate-like adaptive T lymphocytes, thereby impairing the IL-23-dependent induction of IFN-γ.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37875108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025203621&v=2.17.9.post6+86293ac">37875108</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.09.024>10.1016/j.cell.2023.09.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37875108</guid><pubDate> Tue, 24 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Jonathan Bohlen</dc:creator><dc:creator> Qinhua Zhou</dc:creator><dc:creator> Quentin Philippot</dc:creator><dc:creator> Masato Ogishi</dc:creator><dc:creator> Darawan Rinchai</dc:creator><dc:creator> Tea Nieminen</dc:creator><dc:creator> Simin Seyedpour</dc:creator><dc:creator> Nima Parvaneh</dc:creator><dc:creator> Nima Rezaei</dc:creator><dc:creator> Niloufar Yazdanpanah</dc:creator><dc:creator> Mana Momenilandi</dc:creator><dc:creator> Clément Conil</dc:creator><dc:creator> Anna-Lena Neehus</dc:creator><dc:creator> Carltin Schmidt</dc:creator><dc:creator> Carlos A Arango-Franco</dc:creator><dc:creator> Tom Le Voyer</dc:creator><dc:creator> Taushif Khan</dc:creator><dc:creator> Rui Yang</dc:creator><dc:creator> Julia Puchan</dc:creator><dc:creator> Lucia Erazo</dc:creator><dc:creator> Mykola Roiuk</dc:creator><dc:creator> Taja Vatovec</dc:creator><dc:creator> Zarah Janda</dc:creator><dc:creator> Ivan Bagarić</dc:creator><dc:creator> Marie Materna</dc:creator><dc:creator> Adrian Gervais</dc:creator><dc:creator> Hailun Li</dc:creator><dc:creator> Jérémie Rosain</dc:creator><dc:creator> Jessica N Peel</dc:creator><dc:creator> Yoann Seeleuthner</dc:creator><dc:creator> Ji Eun Han</dc:creator><dc:creator> Anne-Sophie L&#39;Honneur</dc:creator><dc:creator> Marcela Moncada-Vélez</dc:creator><dc:creator> Marta Martin-Fernandez</dc:creator><dc:creator> Michael E Horesh</dc:creator><dc:creator> Tatiana Kochetkov</dc:creator><dc:creator> Monika Schmidt</dc:creator><dc:creator> Mohammed A AlShehri</dc:creator><dc:creator> Eeva Salo</dc:creator><dc:creator> Harri Saxen</dc:creator><dc:creator> Gehad ElGhazali</dc:creator><dc:creator> Ahmad Yatim</dc:creator><dc:creator> Camille Soudée</dc:creator><dc:creator> Federica Sallusto</dc:creator><dc:creator> Armin Ensser</dc:creator><dc:creator> Nico Marr</dc:creator><dc:creator> Peng Zhang</dc:creator><dc:creator> Dusan Bogunovic</dc:creator><dc:creator> Aurélie Cobat</dc:creator><dc:creator> Mohammad Shahrooei</dc:creator><dc:creator> Vivien Béziat</dc:creator><dc:creator> Laurent Abel</dc:creator><dc:creator> Xiaochuan Wang</dc:creator><dc:creator> Stéphanie Boisson-Dupuis</dc:creator><dc:creator> Aurelio A Teleman</dc:creator><dc:creator> Jacinta Bustamante</dc:creator><dc:creator> Qian Zhang</dc:creator><dc:creator> Jean-Laurent Casanova</dc:creator><dc:date> 2023-10-24</dc:date><dc:source> Cell</dc:source><dc:title> Human MCTS1-dependent translation of JAK2 is essential for IFN-γ immunity to mycobacteria</dc:title><dc:identifier> pmid:37875108</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.024</dc:identifier></item></channel></rss>